We are currently focussing our research and development efforts on a rare orphan skin fragility disorder  known as RDEB, for which there are currently no treatments available. Leveraging on our polyfunctional cationic polymer gene editing platform delivery system we are presently expanding our pipeline to encompass additional therapeutic targets including Cystic Fibrosis and Inherited Corneal Disorders.

Pipeline Expansion

Following on from our initial target BrB101 for Dystrophic EB, we are currently exploring additional therapeutic targets for other inherited genetic disorders through our R&D platform. BrB102 and BrB103 designed to target Cystic Fibrosis and inherited corneal disorders respectively are undergoing discovery phase at Branca Bunús at present.

---